Please login to the form below

Not currently logged in
Email:
Password:

Onyx Pharma appoints John Osborn SVP global corporate affairs

Joins from Dendreon to lead public and government affairs activities

Dendreon's John Osborn has joined Onyx Pharmaceuticals as senior VP, global corporate affairs.

In his new role at the US-based biopharma, he will lead the company's public and government affairs activities, as well as key stakeholder relationships.

Osborn's most recent position was executive VP, general counsel and secretary at Dendreon, which markets cancer vaccine Provenge.

Prior to his time at Dendreon, he held similar roles at US Oncology and Cephalon.

He also spent time serving with the US Department of State and was a member of the bipartisan United States Advisory Commission on Public Diplomacy in 2008.

“As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the US government,” said Dr Anthony Coles, president and CEO of Onyx.

“John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world.”

20th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptiv Solutions

Aptiv Solutions is a global development services company focused on enhancing clinical trial decision-making, efficiency and productivity for pharmaceutical, biotech...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...